CDC Panel Stops Shy Of Universal Adult Hepatitis B Vaccine Recommendation
ACIP working group proposal for all adults was altered to include an upper age limit for universal hepatitis B vaccination.
You may also be interested in...
Partnerships between big pharma and biotech focused on biologic therapies for hepatitis B could reap the benefit of less competition as lone biotechs, such as Aligos, discontinue their candidates.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Novel agents approved under Real-Time Oncology Review posted a median time to approval of seven months, our Pink Sheet RTOR infographic shows, while other RTOR applications had a median 4.5 month approval time.